Continuous expression of activated factor VII (FVIIa) via gene transfer is a potential therapeutic approach for hemophilia patients with or without inhibitory antibodies to human factor VIII (FVIII) or IX (FIX). Here, we investigate whether gene transfer of an engineered canine FVIIa (cFVIIa) transgene can affect hemostasis in a canine model of hemophilia, a good predictor of efficacy of hemoph...

Surgeries in patients treated prophylactically with emicizumab (including surgical procedures a high risk of postoperative bleeding) are not associated higher risks or technical difficulties compared operations receiving standard replacement therapy. On the contrary, presence blood and its maintenance permanent basic hemostasis allow for reduction doses infusion time bypassing agents. Patients ...

Hemophilia is a bleeding disorder that results from genetic alteration in production of coagulation factors that are important to maintain hemostasis. The commonest type is hemophilia A due to deficiency of factor VIII (FVIII), which is important zymogen co factor for clot formation. Hemophilia A is an X-linked disease that affects males at prevalence of 1:5000-10000. Hemophilia B is due to def...

Background: Acquired hemophilia A (AHA) is a rare bleeding disease due to autoantibodies directed against clotting factor VIII (FVIII). Treatment of AHA consists inhibitor eradication with immunosuppressive therapy (IST) and prompt control obtained bypassing agents or recombinant porcine FVIII (rpFVIII). The latter has recently been licensed for management acute in AHA. Unlike treatment agents,...

Tissue inhibitor of metalloproteinases-l (TIMP-l), the major physiological matrix metalloproteinase inhibitor and a potent antimetastatic factor, also stimulates the growth of erythroid progenitors (erythroid-potentiating activity). We analyzed the relationship between the growth factor activity and protease inhibition by preparing purified TIMP-1 “knockout” proteins lacking in vitro antiproteo...

BACKGROUND Factor (F)VIIa-based bypassing not always provides sufficient hemostasis in hemophilia. OBJECTIVES To investigate the potential of engineered activated factor V (FVa) variants as bypassing agents in hemophilia A. METHODS Activity of FVa variants was studied in vitro using prothrombinase assays with purified components and in FV- and FVIII-deficient plasma using clotting and throm...

the date palm fruit stalk borer is one of the most important pests of date palm in the world. biochemical properties of digestive proteases in oryctes elegans prell larvae were investigated in this research and optimal total proteolytic and trypsin activities were obtained at ph 9.0 and 11.0, respectively. activity staining of protease on sds-page showed one isoform. also, zymogram pattern of t...

Background: Leukemia inhibitor factor (LIF) is a very important pleiotropic cytokine which belongs to interleukin-6 (IL-6) family. LIF exerts multiple effects on different types of cells and tissues with numerous regulatory effects in vivo and in vitro. It is a lymphoid factor, which performs a number of activities including cholinergic neuron differentia‌tion, contro...